Key facts
- IonDx’s last known valuation is $8.5M (May 2025).
- It has raised $680K; the latest was Seed Round ($680K) in May 2025.
- Notable investors include US National Science Foundation, Breakout Labs, Traction on Demand.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for IonDx
- ·The full record, as it builds
Funding rounds
No funding rounds for IonDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IonDx
Operator of a life sciences instrumentation company intended to focus on developing biotherapeutic analytical services to support accelerated drug development. The company uses atmospheric pressure-based ion mobility spectrometry that analyzes biologically relevant native conformations of proteins, protein complexes, and nucleic acid modalities, enabling researchers to conduct comparability studies to create an antibody biotherapeutic drug.
- Sector
- Healthcare
- HQ
- Monterey, CA, United States
- Founded
- 2014
- Employees
- 5
- Website
- iondx.com/
- Ownership
- Privately Held (backing)
IonDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IonDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IonDx in its N-PORT filings yet. We sweep new filings monthly.